FōLIUS LABS® Boswellia offers 65% boswellic acid in an oleoresin extract. This premium, pure and clean-label product is non-GMO, natural, vegan and optimized for purity, with no added excipients. Enjoy the maximum health benefits from this powerful ingredient.
See our research
See our research
Several clinical studies have shown that Boswellia serrata extract at a 65% concentration of boswellic acid can effectively reduce inflammation and pain.
- One randomized double-blind placebo-controlled trial studied the effects of Boswellia serrata extract on patients with osteoarthritis of the knee. The study found that the group treated with Boswellia serrata extract showed significant improvement in knee pain, knee flexion, and walking distance compared to the placebo group. 
- Another study looked at the effects of Boswellia serrata extract on patients with ulcerative colitis. The study found that patients treated with Boswellia serrata extract had a significant reduction in symptoms compared to the placebo group. 
- In addition, Boswellia serrata extract at a 65% concentration of boswellic acid has been shown to have anti-cancer properties. A study on breast cancer cells found that Boswellia serrata extract could suppress the growth and invasion of cancer cells. 
Overall, Boswellia serrata extract at a 65% concentration of boswellic acid is the most effective Boswellia supplement due to its anti-inflammatory and pain-relieving properties. Its efficacy is supported by various clinical studies, making it a popular natural remedy for inflammatory conditions.
- Sengupta, K., et al. "A double-blind, randomized, placebo-controlled study evaluating the efficacy and safety of Boswellia serrata extract in the management of osteoarthritis of the knee." International journal of Ayurveda research 1.4 (2010): 211.
- Gupta, I., et al. "Effects of Boswellia serrata gum resin in patients with ulcerative colitis." European journal of medical research 14.5 (2009): 205.
- Pang, X., et al. "Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family." Carcinogenesis 33.12 (2012): 2441-2449.